氯沙坦对原发性高血压体液免疫水平的影响

目的：探讨氯沙坦对原发性高血压体液免疫水平的影响。方法：64例住院或门诊原发性高血压患者口服氯沙坦50mg/d，疗程4周。结果：原发性高血压患者经氯沙坦治疗4周后，IgG、IgM、IgA、C3、CIC值与治疗前相比有非常显著差异（P＜0．01）。分级研究显示：1级高血压患者经氯沙坦治疗后IgG、CIC差异非常显著（P＜0．01），IgA,C3有显著差异；2级高血压患者治疗后IgG、C3、CIC差异非常显著（P＜0．01），IgG、IgM有显著差异；3级高血压患者治疗后IgG、C3、CIC有非常显著差异（P＜0．01）。结论：氯沙坦可改善原发性高血压患者体液免疫的异常。

The Influence of Losatan on Humoral Immunity Levelof Patients with Essential Hypertension

Objective:To explore the influence of Losartan on humoral immunity level of patients with essential hypertension. Methods: 64 in- and out-patients with essential hypertension were given Losartan pills at a dose of 50/d for 4 weeks, and a series of laboratory tests were taken on the plasma of patients before and after the treatment. Results: the plasma levels of IgG, IgM, IgA, C 3 and CIC decreased (P<0.01) after the treatment. The grading study results showed that, after the treatment of Losartan, for patients of grade 1, the plasma levels of IgG, CIC got much lower than those before the treatment (P<0.01), and the plasma IgA and C 3 also decreased; for patients of grade 2, plasma levels of IgG, C 3, CIC,IgA and IgM decreased; for patients of grade 3 , plasma levels of IgG, C 3, and CIC decreased (P<0.01). Conclusion: Losartan could improve the humoral immunity of patients with essential hypertension.